Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05588323
Study type Interventional
Source Shionogi Inc.
Contact Shionogi Clinical Trials Administrator Clinical Support Help Lin
Phone 800-849-9707
Email Shionogiclintrials-admin@shionogi.co.jp
Status Recruiting
Phase Phase 1/Phase 2
Start date January 4, 2023
Completion date August 13, 2024

See also
  Status Clinical Trial Phase
Completed NCT01333540 - A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation Phase 2
Completed NCT01309841 - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Completed NCT01323790 - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Completed NCT01395524 - A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Completed NCT01336205 - Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3